论文部分内容阅读
2010年7月13日,FDA发布来氟米特(leflunomide)可导致严重肝损伤的安全通报。来氟米特临床用于治疗活动性类风湿性关节炎[1]。来氟米特曾被禁用于孕妇和待孕妇女。2003年,来氟米特的处方信息提示其可导致严重的肝损伤,并建议患者每6～8周进行肝功能检测。鉴于2002年8月至2009年5
On July 13, 2010, the FDA released a safety bulletin on leflunomide, which can cause severe liver damage. Leflunomide is used to treat active rheumatoid arthritis [1]. Leflunomide has been banned in pregnant and pregnant women. In 2003, prescribing information for leflunomide suggested that it could cause severe liver damage and recommended that patients be tested for liver function every 6 to 8 weeks. In view of August 2002 to 2009 5